(Q37140676)

18 August 2017

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel (English)

1 reference

18 August 2017

1 reference

1 reference

8

Alex Sparreboom

1 reference

18 August 2017

Erin R Gardner

1

1 reference

18 August 2017

William L Dahut

2

1 reference

18 August 2017

Charity D Scripture

3

1 reference

18 August 2017

Jacquin Jones

4

1 reference

18 August 2017

Jeanny B Aragon-Ching

5

1 reference

18 August 2017

Neil Desai

6

1 reference

18 August 2017

Michael J Hawkins

7

1 reference

18 August 2017

William D Figg

9

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

18 August 2017

Clinical Cancer Research

1 reference

18 August 2017

14

1 reference

18 August 2017

13

1 reference

18 August 2017

4200-4205

1 reference

Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Measurement of fraction unbound paclitaxel in human plasma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Mechanism-based pharmacokinetic model for paclitaxel

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661025

Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18594000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18594000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-07-4592

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

18594000

1 reference